COL18A1 and non-small cell lung carcinoma: In a retrospective comparison of rh - endostatin plus pemetrexed/cisplatin and pemetrexed/cisplatin in advanced NSCLC, the median progression - free survival (PFS) was 10 months in the rh - endostatin group and 8.2 months in the chemotherapy group, but the difference was not statistically significant (P = 0.13) (29).